Drug Trial Radar · NCT03335371
Evaluation of TTP399 in Patients With Type 1 Diabetes
Last checked: Nov 19, 2026Latest source record: Jul 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
115
Actual
Start
Oct 25, 2017
Primary completion
Dec 20, 2019
Study completion Jan 6, 2020
Sponsor
- Lead sponsor
- vTv TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- Juvenile Diabetes Research Foundation
- First posted
- Nov 7, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of TTP399 in Type 1 diabetics. This study will be in 2 phases: phase 1 will evaluate the safety of different TTP399 dosage regimens over 1 week of daily dosing. Phase 2 will evaluate the safety and efficacy of a TTP399 dosing regimen over 12 weeks of daily dosing.
Conditions
- Diabetes Mellitus, Type 1
Interventions
TTP399Drug
Phase 1: Participants will receive TTP399 administered orally up to 1200 mg taken once daily for 7 days
TTP399Drug
Phase 2: Participants will receive TTP399 administered orally 800 mg taken once daily for 12 weeks
Placebo Oral TabletDrug
Phase 2: Participants will receive Placebo oral tablets for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12Time frame: Baseline (Day 1) to Week 13
- Sentinel - Area Under the Concentration Time Curve (AUC)Time frame: Predose, 60, 90, 120, 150, 180, 240, 360 (6hr) and 540min (9hr) after dosing.
- Sentinel - Maximum Drug Concentration (Cmax)Time frame: Predose, 60, 90, 120, 150, 180, 240, 360 (6hr) and 540min (9hr) after dosing.
- Sentinel - Time to Maximum Concentration (Tmax)Time frame: Predose, 60, 90, 120, 150, 180, 240, 360 (6hr) and 540min (9hr) after dosing.
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
USC Westside Center for Diabetes
Beverly Hills, California
AMCR Institute
Escondido, California
University of Colorado Barbara Davis Center
Aurora, Colorado
Atlanta Diabetes Associate
Atlanta, Georgia
Rocky Mountain Diabetes Center
Idaho Falls, Idaho
Iowa Diabetes Research
West Des Moines, Iowa
Mountain Diabetes and Endocrine Center
Asheville, North Carolina
UNC Diabetes Care Center
Chapel Hill, North Carolina
Duke University Diabetes Research Clinic
Durham, North Carolina
Diabetes & Endocrinology Consultants
Morehead City, North Carolina
PMG Research of Wilmington
Wilmington, North Carolina
Wake Forest
Winston-Salem, North Carolina
Intend Research
Norman, Oklahoma
Dallas Diabetes Research Center
Dallas, Texas
University of Washington Medicine Diabetes Institute
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.